Takol Chareonsirisuthigul

Dr. Takol Chareonsirisuthigul

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JPJirawan Panachan
Jirawan Panachan
NRNapat Rojsirikulchai
Napat Rojsirikulchai
NPNutkridta Pongsakul
Nutkridta Pongsakul
LKLadawan Khowawisetsut
Ladawan Khowawisetsut
PPPongpak Pongphitcha
Pongpak Pongphitcha
SCSomchai Chutipongtanate
Somchai Chutipongtanate
MYCN amplification is the strongest predictor of high-risk neuroblastoma (NB). The standard procedure to detect MYCN status requires invasive procedures. Extracellular vesicles (EVs) contain molecular signatures of originated cells, present in biofluids, and serve as an invaluable source for cancer liquid biopsies. This study aimed to establish an EV-based method to detect the MYCN status of NB. Two EV subtypes, i.e., microvesicles (MVs) and exosomes, were sequentially isolated from the culture supernatant by step-wise centrifugation, ultrafiltration, and size-exclusion chromatography. Quantitative RT-PCR was performed to detect MYCN mRNA. As a result, MYCN mRNA was detectable in the MVs, but not exosomes, of MYCN-amplified NB cells. MYCN mRNA-containing MVs (MYCN-MV) were successfully detected in three distinct MYCN-amplified NB cell lines but absent in three MYCN non-amplification cells. The simulated samples were prepared by pulsing MVs into human serum. MYCN–MV detection in the simulated samples showed a less interfering effect from the human blood matrix. Validation using clinical specimens (2 mL bone marrow plasma) obtained from patients at various disease stages showed a promising result. Five out of six specimens of MYCN-amplified patients showed positive results, while there were no false positives in four plasma samples of the MYCN non-amplification group. This study communicated a novel EV-based method for detecting the MYCN status of pediatric NB based on MYCN mRNA contents in MVs. Future studies should be pursued in a prospective cohort to determine its true diagnostic performance.

1 August 2018 in Cancer Genetics
Verified
Journal Article
Closed access
YRYanisa Rattanapan
Yanisa Rattanapan
VKVeerawat Korkiatsakul
Veerawat Korkiatsakul
AKAdcharee Kongruang
Adcharee Kongruang
TCTakol Chareonsirisuthigul
Takol Chareonsirisuthigul
BRBudsaba Rerkamnuaychoke
Budsaba Rerkamnuaychoke
SWSarikapan Wilailak
Sarikapan Wilailak

14 May 2014 in Case Reports in Genetics
Verified
Journal Article
Open access
PDF file
TCTakol Chareonsirisuthigul
Takol Chareonsirisuthigul
SWSuchin Worawichawong
Suchin Worawichawong
RPRachanee Parinayok
Rachanee Parinayok
PPPatama Promsonthi
Patama Promsonthi
BRBudsaba Rerkamnuaychoke
Budsaba Rerkamnuaychoke
Fetal trisomy 16 is considered uniformly lethal early in gestation. It has been reported to be associated with the variability of clinical features and outcomes. Mosaic trisomy 16 leads to a high risk of abnormality in prenatal cases. Intrauterine growth retardation (IUGR) is a common outcome of mosaic trisomy 16. Herein, we report on the case of Thai male IUGR fetus with trisomy 16 mosaicism. The fetal body was too small. Postmortem investigation of placenta revealed the abnormality including small placenta with furcated cord insertion and single umbilical cord artery. Cytogenetic study demonstrated trisomy 16 that was found 100% in placenta and only 16% in the fetal heart while other organs had normal karyotype. In addition, cardiac and other internal organs examination revealed normal morphology.

1 March 2021 in MicroRNA
Verified
Journal Article
Closed access
PDF file
YRYanisa Rattanapan
Yanisa Rattanapan
VKVeerawat Korkiatsakul
Veerawat Korkiatsakul
AKAdcharee Kongruang
Adcharee Kongruang
TSTeerapong Siriboonpiputtana
Teerapong Siriboonpiputtana
BRBudsaba Rerkamnuaychoke
Budsaba Rerkamnuaychoke
TCTakol Chareonsirisuthigul
Takol Chareonsirisuthigul
Background: Ovarian cancer is the most deadly cancer that requires novel diagnostics and therapeutics. MicroRNAs are viewed as essential gene regulatory elements involved in different pathobiological mechanisms of many cancers, including ovarian cancer. Objective: This study examined the relationship between microRNA (miRNA) expression and response to platinum-based chemotherapy. Methods: Genome-wide miRNA expression analysis was conducted using Epithelial Ovarian Cancer (EOC) tissues from 25 patients with 17 malignant tumors and eight benign ovarian tumors. Candidate miRNAs that respond to platinum-based chemotherapy were selected for validation by quantitative RT-PCR. Result: Among 2,578 mature human miRNAs, high expression of miR-483-5p correlated with poor responses to platinum-based chemotherapy in EOC patients. Furthermore, high levels of miR-483-5p in the resistant group suppressed expression of the apoptotic regulator TAOK-1. Conclusion: A possible marker for the prediction of chemotherapy response and resistance in patients may be miR-483-5p. Choosing the right treatment for each patient with EOC can avoid the risk of developing chemotherapy resistance.

1 January 2022 in Cytogenetic and Genome Research
Verified
Journal Article
Open access
PDF file
RPRachanee Parinayok
Rachanee Parinayok
PAPrapatsorn Areesirisuk
Prapatsorn Areesirisuk
TCTakol Chareonsirisuthigul
Takol Chareonsirisuthigul
WBWarakorn Buchachat
Warakorn Buchachat
ฺRฺีBudsaba Rerkamnuaychoke
ฺีBudsaba Rerkamnuaychoke
Abortion is a common pregnancy complication. Fetuses with several types of chromosomal abnormalities are aborted during the first trimester, while others have a better chance of surviving. This research aims to study and compare the incidence and types of fetal chromosomal abnormalities during the first trimester of Thai pregnant women between miscarriages and intrauterine survivals. Cytogenetic and BACs-on-Beads™ assays were assessed from 2010 to 2020 in Ramathibodi Hospital using first trimester samples of 265 chorionic villi as a retrospective study. Chromosomal abnormalities were observed in 135 cases (50.94%) including 38.11% miscarriages and 12.83% intrauterine survivals. In total, 75.56% single autosomal trisomies, 18.52% sex chromosome aneuploidies, 5.19% double aneuploidies, and 0.74% structural abnormalities were detected. In miscarriages, all chromosomes were involved in abnormalities except chromosomes 1, 5, 8, 9, 11, and 17, while survivals had only trisomy 13, 18, 21, and sex chromosome aneuploidy. Trisomy 16 and 18 were the most common abnormalities in miscarriages and intrauterine survivals, respectively. The highest rate of chromosomal aberrations was demonstrated in 8–9+6 and 12–13+6 weeks of gestation in miscarriages and intrauterine survivals, respectively. Correlation between chromosomal abnormalities and maternal age <35 years and ≥35 years was significant (p < 0.05) in intrauterine survival and first trimester groups.

8 October 2022 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
YRYanisa Rattanapan
Yanisa Rattanapan
NCNurdina Charong
Nurdina Charong
SNSodsai Narkpetch
Sodsai Narkpetch
TCTakol Chareonsirisuthigul
Takol Chareonsirisuthigul
The para-Bombay phenotype, or H-deficient secretor, results from different mutations of the FUT1, with or without the FUT2 mutation. Consequently, there is an absent or weak expression of the H antigen on red blood cells (RBCs). Routine ABO blood grouping for two siblings with blood group O showed discrepant results with their parental blood group AB. Fragments encompassing the entire coding region of the FUT1 and FUT2 genes were investigated. Blood and saliva specimens were collected to verify the correct ABO grouping by cell grouping, serum grouping and the hemagglutination inhibition (HI) test, respectively. The FUT1 and FUT2 genomes were identified using the whole-exome sequencing (WES) in two children's DNA blood specimens and may have caused, or been relative to, their blood group. Genetic variations of the FUT1 and FUT2 genes have been investigated in the other family members using the Sanger sequencing. The serologic reaction results of the proband revealed that A, B and H antigens were absent on RBCs, and that the serum contained anti-H. However, ABH and AH antigens were present in the saliva PB1 and PB2, respectively. The probands PB1 and PB2 were assigned as AB and A blood groups, respectively. Blood genotyping confirmed that heterozygous mutations of the FUT1 gene, c.551_552delAG, were identified. Three family members, PB3, PB, and PB8, also showed normal ABO blood groups, but their genotypes were also the FUT1 mutation c.551_552delAG. The FUT1 mutation c.551_552delAG may result in the reduced or absent H antigen production on RBCs, which characterizes the para-Bombay phenotypes. Blood genotyping is essential if these individuals need a blood transfusion or are planning to donate blood.